Literature DB >> 6895415

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy.

F B Hagemeister, L M Fuller, J A Sullivan, L North, W Velasquez, F G Conrad, P McLaughlin, J J Butler, C C Shullenberger.   

Abstract

Three treatment programs for Stage I and II mediastinal Hodgkin disease (established by laparotomy) were compared. Involved-field radiotherapy + MOPP gave a disease-free survival rate of 97%, significantly different from 62% and 55% for involved and extended fields, respectively. Corresponding survival figures of 97%, 88%, and 84% were not significantly different statistically due to salvage with radiotherapy and/or chemotherapy. Among patients given radiotherapy alone, the survival figure of 94% for limited mediastinal disease was significantly better than 63% for extensive mediastinal and hilar disease; corresponding disease-free figures of 72% and 35% were also significantly different. Constitutional symptoms were an important prognostic factor in disease-free survival following the use of involved fields; hilar disease was important only with large mediastinal masses. Most relapses were intrathoracic; MOPP alone salvaged only 47%. Treatment of Stage I and II Hodgkin disease should be based on symptoms, extent of mediastinal disease, and hilar involvement.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895415     DOI: 10.1148/radiology.141.3.6895415

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Radiation therapy alone versus radiation therapy and chemotherapy in the management of Hodgkin's disease.

Authors:  L D Glenn; P P Kumar
Journal:  J Natl Med Assoc       Date:  1990-02       Impact factor: 1.798

2.  Hodgkin's disease and a mediastinal tumor.

Authors:  G Prindull; W Beck; G Rahlf; H Gadner
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

Review 3.  Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.

Authors:  J G Franklin; M D Paus; A Pluetschow; L Specht
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.